The US FDA has proposed an end to most types of compounding of semaglutide, tirzepatide, and liraglutide. The agency said in a statement it has determined there is no longer a clinical need for ...

Demand for popular weight loss drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) has long outpaced supply, forcing many patients with obesity to visit compounding pharmacies to get ...